METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES

1 . A method of treating an infectious disease comprising administering to an animal a compound having the structure of any one of Formulas I and II, or a pharmaceutically acceptable salt or pro-drug thereof:

wherein:

the dashed lines represent a single or a double bond;

each R 1 is separately a hydrogen, a halogen, a cyano, a nitro, an azido, a hydroxy, or a thiocyano, or selected from the group consisting of optionally substituted: C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio, oxysulfonyl, carboxy, thio, sulfoxide, sulfone, sulfonate esters, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;

n is 1 or 2, where if n is 2, then each R 1 can be the same or different;

m is 1 or 2, where if m is 2, then each R 4 can be the same or different;

R 2 is a hydrogen, a halogen, a cyano, a nitro, an azido, a hydroxy, or a thiocyano, or selected from the group consisting of optionally substituted: C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio, oxysulfonyl, carboxy, thio, sulfoxide, sulfone, sulfonate esters, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;

R 3 is a halogen or selected from the group consisting of optionally substituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl;

each of E 1 , E 3 , E 4 and E 5 is an optionally substituted heteroatom;

E 2 is an optionally substituted heteroatom or —CH 2 — group;

each R 4 is separately a halogen, a cyano, a nitro, an azido, or a thiocyano, or selected from the group consisting of optionally substituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, hydroxy, aminocarbonyl, aminocarbonyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio, oxysulfonyl, carboxy, thio, sulfoxide, sulfone, sulfonate esters, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl; and

wherein the infectious disease is selected from the group consisting of Bacteremia, Botulism, Brucellosis, Clostridium Difficile, Campylobacter Infection, Cat Scratch Disease, Chancroid, Chlamydia , Cholera, Clostridium Perfringens , Bacterial Conjunctivitis, Diphtheria, E. Coli Infections, Ehrlichiosis, Epididymitis, Gardnerella , Gas Gangrene, Gonorrhea, Helicobacter Pylori, Haemophilus , Influenzae B, Impetigo, Intertrigo, Leprosy, Listeriosis, Lyme Disease, Methicillin Resistant Staphylococcus Aureus , Orchitis, Osteomyelitis, Otitis, Media Pertussis, Plague, Pneumonia, Prostatitis Pyelonephritis, Q Fever, Rocky Mountain Spotted Fever, Salmonellosis, Scarlet Fever, Sepsis, Shigellosis, Staphylococcal Infections, Streptococcal Infections, Syphilis, Tetanus, Toxic Shock Syndrome, Trachoma, Traveller's Diarrhea, Tuberculosis, Tularemia, Typhoid Fever, Typhus Fever, Urinary Tract Infections, Bacterial Vaginosis, Pertussis, Yersiniosis, malaria, African trypanosomiasis, candidiasis, histoplasmosis, blastomycosis, coccidioidomycosis, aspergillisis, and mucormycosis.

2 . The method of claim 1 , wherein the compound is Salinosporamide A:

3 . The method of claim 1 , wherein the infectious disease is caused by a bacterial infection.

4 . The method of claim 3 , wherein the compound is Salinosporamide A:

5 . The method of claim 3 , wherein the bacterial infectious disease is Tuberculosis.

6 . The method of claim 5 , wherein the compound is Salinosporamide A:

7 . The method of claim 5 , wherein the bacteria causing Tuberculosis is selected from the group consisting of Mycobacterium bovis, Mycobacterium africanum and Mycobacterium microti.

8 . The method of claim 7 , wherein the compound is Salinosporamide A:

9 . The method of claim 5 , wherein the bacteria causing Tuberculosis is Mycobacterium tuberculosis.

10 . The method of claim 9 , wherein the compound is Salinosporamide A:

11 . The method of any one of the claims 1 , further comprising co-administering one or more anti-infective agent(s).

12 . The method of claim 11 , wherein the compound is Salinosporamide A:

13 . The method of the claim 11 , wherein the anti-infective agent(s) is selected from the group consisting of isoniazid, rifampin, ethambutol, pyrazinamide, rifater, streptomycin, rifapentine and epoxomicin.

14 . The method of claim 13 , wherein the compound is Salinosporamide A:

15 . The method of any one of the claims 1 , wherein the animal is a human.

16 . The method of claim 15 , wherein the compound is Salinosporamide A: